<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224274</url>
  </required_header>
  <id_info>
    <org_study_id>Hypothermia: Clopi vs Tica</org_study_id>
    <nct_id>NCT02224274</nct_id>
  </id_info>
  <brief_title>Antiplatelet Therapy After Cardiac Arrest</brief_title>
  <official_title>Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is growing evidence that standard dual antiplatelet therapy with acetylsalicylic acid
      (ASA) and clopidogrel is not as effective in the setting of therapeutic hypothermia after
      cardiac arrest as in normothermic patients. The reasons for this are probably slower
      gastrointestinal motility, absorption and liver metabolism required for clopidogrel to take
      action. Since ticagrelor has faster intestinal absorption and no need for liver metabolism we
      expect its effect to be good even in patients with therapeutic hypothermia after cardiac
      arrest. Patients treated with therapeutic hypothermia after cardiac arrest and percutaneous
      coronary intervention will be randomised into two groups. One will be treated with ASA and
      clopidogrel and the other with ASA and ticagrelor. Blood samples will be collected before and
      2, 4, 12, 22 and 48 hours after P2Y12 inhibitor administration. Platelet function will be
      measured by VerifyNow P2Y12 assay and by Multiplate ADPTest. Differences between the groups
      will be analysed.

      Hypothesis: Antiplatelet therapy with ticagrelor is more effective than therapy with
      clopidogrel in the comatose survivors of cardiac arrest treated with therapeutic hypothermia
      and percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VerifyNow PRUTest - % inhibition</measure>
    <time_frame>12 h after P2Y12 inhibitor administration</time_frame>
    <description>VerifyNow PRUTest produces 3 values: PRU, BASE and % inhibition. PRU reflects P2Y12 inhibitor effect, BASE reflects basal platelet reactivity independent of P2Y12 inhibitor use and % inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Cardiac Arrest</condition>
  <condition>Postresuscitation Syndrome</condition>
  <condition>Myocardial Infarction (STEMI and NSTEMI)</condition>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients will be treated with clopidogrel 600 mg loading and than 75 mg/24 h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will be treated with ticagrelor 180 mg loading and than 90 mg/12 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>Clopidogrel</arm_group_label>
    <other_name>Clopidogrel (Plavix)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Ticagrelor (Brilique)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male over 18 years old

          -  Unconscious survivors of cardiac arrest treated with therapeutic hypothermia

          -  Acute coronary syndrome (NSTEMI or STEMI) as a reason of cardiac arrest

          -  PCI with stent implantation

          -  Provision of informed consent prior to any study specific procedures is impossible
             because subjects are unconscious at the moment of inclusion

        Exclusion Criteria:

          -  Use of any P2Y12 inhibitors in last 10 days

          -  Use of prasugrel before and 48 hours after loading dose of P2Y12 inhibitor

          -  Use of eptifibatide before and 48 hours after loading dose of P2Y12 inhibitor

          -  Thrombocytopenia (&lt;50*109/L)

          -  Allergic reaction to acetylsalicylic acid, clopidogrel or ticagrelor

          -  Ticagrelor contraindications: previous intracranial bleeding, active pathological
             bleeding, moderate to severe hepatic impairment, heart rate &lt; 40/min at presentation

          -  Suspected or confirmed pregnancy

          -  Use of bivalirudin before and 48 hours after loading dose of P2Y12 inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Centre Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Steblovnik K, Blinc A, Bozic-Mijovski M, Kranjec I, Melkic E, Noc M. Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia. EuroIntervention. 2015 Apr;10(12):1418-24. doi: 10.4244/EIJY14M05_02.</citation>
    <PMID>24800722</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013 Aug 17;382(9892):614-23. doi: 10.1016/S0140-6736(13)61170-8. Epub 2013 Jul 26. Erratum in: Lancet. 2014 Mar 29;383(9923):1128.</citation>
    <PMID>23890998</PMID>
  </reference>
  <reference>
    <citation>Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009 Dec 22;120(25):2577-85. doi: 10.1161/CIRCULATIONAHA.109.912550. Epub 2009 Nov 18.</citation>
    <PMID>19923168</PMID>
  </reference>
  <reference>
    <citation>Gorjup V, Radsel P, Kocjancic ST, Erzen D, Noc M. Acute ST-elevation myocardial infarction after successful cardiopulmonary resuscitation. Resuscitation. 2007 Mar;72(3):379-85. Epub 2006 Dec 11.</citation>
    <PMID>17161902</PMID>
  </reference>
  <reference>
    <citation>Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002 Feb 21;346(8):557-63.</citation>
    <PMID>11856794</PMID>
  </reference>
  <reference>
    <citation>Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos K, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G. Response to letter regarding article, &quot;Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction&quot;. Circ Cardiovasc Interv. 2013 Apr;6(2):e29. doi: 10.1161/CIRCINTERVENTIONS.113.000134.</citation>
    <PMID>23591428</PMID>
  </reference>
  <reference>
    <citation>Součková L, Opatřilová R, Suk P, Čundrle I Jr, Pavlík M, Zvoníček V, Hlinomaz O, Šrámek V. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR). Eur J Clin Pharmacol. 2013 Mar;69(3):309-17. doi: 10.1007/s00228-012-1360-0. Epub 2012 Aug 14.</citation>
    <PMID>22890586</PMID>
  </reference>
  <reference>
    <citation>Bjelland TW, Hjertner Ø, Klepstad P, Kaisen K, Dale O, Haugen BO. Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation. 2010 Dec;81(12):1627-31. doi: 10.1016/j.resuscitation.2010.07.002. Epub 2010 Aug 19.</citation>
    <PMID>20727659</PMID>
  </reference>
  <reference>
    <citation>Polderman KH. Mechanisms of action, physiological effects, and complications of hypothermia. Crit Care Med. 2009 Jul;37(7 Suppl):S186-202. doi: 10.1097/CCM.0b013e3181aa5241. Review.</citation>
    <PMID>19535947</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2014</study_first_submitted>
  <study_first_submitted_qc>August 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2014</study_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Ljubljana</investigator_affiliation>
    <investigator_full_name>Marko Noc</investigator_full_name>
    <investigator_title>Marko Noc, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Antiplatelet Therapy</keyword>
  <keyword>Cardiac Arrest</keyword>
  <keyword>Therapeutic hypothermia</keyword>
  <keyword>Myocardial infarction (STEMI and NSTEMI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Heart Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 23, 2017</submitted>
    <returned>March 13, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

